Boehringer, Eli Say Release Two-Year, Phase III Lingaliptin Data

Healthcare

United States

Europe

Americas

Germany

Industrials

Science

Boehringer Ingelheim and Eli Lilly and Co. said a 102-week Phase III study for linagliptin showed meaningful and durable reductions in blood glucose for adults with type 2 diabetes.

Bloomberg subscribers can save articles and view them from any device.

Upgrade to an unlimited subscription to save articles and view them from anywhere.

Bloomberg subscribers can send up to {count} articles a month to anyone to read for free, including non-subscribers.

Upgrade your subscription to send up to {count} articles a month to anyone to read for free, including non-subscribers.

Copy article link

Hello,<p>A Bloomberg.com subscriber thought you might want to read this story. To read it, all you need to do is click on the link – no subscription necessary. (Please note the link will only be valid for {days} days.)

Email article link

Please try again. If the problem persists, please contact customer support.

Something went wrong

We've doubled your gift articles this month. Share up to {count} articles with friends, family or colleagues.

As a subscriber, you can gift up to {count} articles this month. The recipient can read the full article for free – no subscription necessary.

As a subscriber, you can gift up to {count} articles each month. The recipient can read the full article for free – no subscription necessary.